Neurizon Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NUZ.AX research report →
Price Chart
About the company
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases.
- CEO
- Ben Dingle
- IPO
- 2001
- Employees
- 36
- HQ
- Melbourne, VIC, AU
Get TickerSpark's AI analysis on NUZ.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $46.51M
- P/E
- -1.61
- PEG
- -0.02
- P/S
- 0.00
- P/B
- 9.47
- EV/EBITDA
- -2.29
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -254.33%
- ROIC
- -653.88%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-18,475,656
- Net Income
- $-16,593,619-83.7%
- EPS
- $-0.04-52.9%
- OCF Growth
- -176.5%
- FCF Growth
- -176.6%
- 52W High
- $0.17
- 52W Low
- $0.06
- 50D MA
- $0.06
- 200D MA
- $0.08
- Beta
- 1.32
- RSI (14)
- 45
- Avg Volume
- 859.80K
No earnings-call transcripts are available for NUZ.AX yet.
- Free Float
- 52.4%
- Shares Outstanding
- 775.10M
- Float Shares
- 406.10M
Our NUZ.AX coverage
Recent articles, reports, and earnings notes.
No research on NUZ.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NUZ.AX report →Adobe trades revenue for reach as AI monetization stays elusive
proactiveinvestors.com · Jun 12
Neurizon passes halfway mark in HEALEY ALS trial as NUZ-001 dosing accelerates
proactiveinvestors.com · Jun 12
Flutter to quit LSE and trade solely in New York
proactiveinvestors.com · Jun 12
HEALEY ALS Platform Trial Regimen I expands to 240 participants
gurufocus.com · May 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.